Progress of studies on DOTATATE-based α/β radionuclide therapy for neuroendocrine neoplasm
10.3760/cma.j.cn321828-20220707-00216
- VernacularTitle:基于DOTATATE的α/β放射性核素治疗神经内分泌肿瘤的研究进展
- Author:
Delong HUANG
1
;
Junhao WU
;
Yuhang HE
;
Yuanhang HAN
;
Chunbo ZHANG
;
Qiuya YANG
Author Information
1. 西南医科大学临床医学院，泸州 646000
- Keywords:
Neuroendocrine tumors;
Radioisotopes;
Alpha particles;
Beta particles;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(10):627-630
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine neoplasm (NEN) is a type of heterogeneous tumor that originates from peptidergic neurons and neuroendocrine cells. The presence of over-expressed somatostatin receptors (SSTR) on the surface of NEN tumor cells has led to the administration of radiolabeled somatostatin analogs (SSA) in combination with over-expressed SSTR, which is called peptide receptor radionuclide therapy (PRRT). The 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacceticacid- D-Phe1-Tyr3-Thr8-octreotide (DOTATATE)-based α/β radionuclide therapy is one of the representative therapeutic methods of PRRT. This article reviews the progress of research on α/β radionuclide therapy based on DOTATATE and its related combination therapy, drug toxicity and safety, as well as expectation for modalities with clinical value for NEN treatment.
